Chest
-
BronchiectasisSESSION TYPE: Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 09:00 AM - 10:00 AMPURPOSE: Non-cystic fibrosis bronchiectasis is a multicomponent disease associated with increased morbidity and mortality. Using data from 608 patients attending a specialist bronchiectasis clinic in Edinburgh, UK, the Bronchiectasis Severity Index (BSI) has recently been developed as a composite clinical prediction tool in bronchiectasis. The score consists of 8 commonly measured clinical parameters reflecting age, BMI, MRC dyspnoea score, FEV1%, bacterial colonisation, radiological extent, exacerbation frequency and prior hospitalization with subsequent classification into low, intermediate and high risk groups. ⋯ The following authors have nothing to disclose: Melissa McDonnell, James Chalmers, Pieter Goemmine, Stefano Aliberti, Sara Lonni, John Davison, Lucy Poppelwell, Walid Salih, Alberto Pesci, Lieven Dupont, Thomas Fardon, Adam Hill, Anthony De SoyzaNo Product/Research Disclosure Information.
-
COPD Rehabilitation PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Chronic obstructive pulmonary disease (COPD) impacts negatively on the quality of life of patients. Several studies have shown that acute exacerbations (AEs) decrease health-related quality of life, pulmonary function and survival of COPD patients. The objective of the present study was to examine the effects of a physical therapy program on quality of life in COPD patients hospitalized due to an acute exacerbation. ⋯ The following authors have nothing to disclose: Irene Torres-Sánchez, Marie Carmen Valenza, Gerald Valenza-Demet, Irene Cabrera-Martos, María José Flores-Barba, Angela Ruíz-SáezNo Product/Research Disclosure Information.
-
Thoracic SurgerySESSION TYPE: Slide PresentationsPRESENTED ON: Saturday, March 22, 2014 at 09:00 AM - 10:00 AMPURPOSE: Patients with non-small cell lung cancer (NSCLC) and synchronous brain metastases (BMs) on initial diagnosis, who presented with neurological deficits, had a short median survival and lower quality of life (QOL). We analyzed our experiences with surgical treatment of patients with NSCLC who had neurologically symptomatic, synchronous BMs. ⋯ The following authors have nothing to disclose: Minkwang Byun, Wou-Young ChungNo Product/Research Disclosure Information.
-
COPD Epidemiology & Physiology PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: assessing the function of the right side of the heart .along with diagnosing of pulmonary hypertension and studying the hemodynamic abnormalities, thus Studying functional limitations of pulmonary hypertension on COPD patients. ⋯ The following authors have nothing to disclose: Medhat Soliman, Youssef Ameen, Usama AboelhassanNo Product/Research Disclosure Information.
-
COPD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) is being developed for treatment of COPD. This study assessed the efficacy and safety of two twice-daily (BID) FDCs vs monotherapies and placebo. ⋯ Dave Singh: Grant monies (from industry related sources): AstraZeneca, GlaxoSmithKline, Chiesi, Boehringer Ingleheim, Roche, Novartis, Cipla, Almirall and Merck, Consultant fee, speaker bureau, advisory committee, etc.: AstraZeneca, GlaxoSmithKline, Chiesi, Boehringer Ingleheim, Roche, Novartis, Cipla, Almirall and Merck Paul Jones: Consultant fee, speaker bureau, advisory committee, etc.: Almirall S.A., Consultant fee, speaker bureau, advisory committee, etc.: Forest Laboratories, Inc. Eric Bateman: Consultant fee, speaker bureau, advisory committee, etc.: Almirall S.A., Consultant fee, speaker bureau, advisory committee, etc.: Forest Laboratories, Inc., Grant monies (from industry related sources): E D Bateman's has received payment from Almirall for participation in clinical trials Stephanie Korn: Consultant fee, speaker bureau, advisory committee, etc.: Almirall Cristina Serra: Employee: Almirall S.A. Eduard Molins: Employee: Almirall S.A. Cynthia Caracta: Employee: Almirall S.A. Esther Garcia Gil: Employee: Almirall S.A. Anne Leselbaum: Employee: Almirall S.A.This abstracts presents the results of a double blind, randomized Phase III trial of a fixed combination of two products, each of which are approved as monotherapies for the treatment of COPD.